Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial.

ABSTRACT:

Background

PCSK9 inhibitors are lipid-lowering agents with pleiotropic properties including immune-inflammatory modulation. However, the effects of PCSK9 inhibitors on the peripheral immune profile of patients with acute ischemic stroke (AIS) remain unknown. In this analysis, we aim to further investigate the impact of PCSK9 inhibitor evolocumab on clinical outcomes, immune responses, and cytokines in AIS patients.

Methods

In this study, a total of 100 patients with AIS were included for the current analysis (n = 50 for combination therapy of evolocumab and atorvastatin, PI group, n = 50 for atorvastatin monotherapy, AT group). Blood samples were collected at baseline and 7 days after evolocumab administration. T lymphocyte subsets, T helper (Th) cell subsets,

SUBMITTER: Liu J 

PROVIDER: S-EPMC12682626 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature